HSHarmeet Singh

Harmeet Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Harmeet Singh has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Guiying Nie

    Implantation and Pregnancy Research Laboratory, School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia

    2 shared publications
  • Yao Wang

    Implantation and Placental Developmental Laboratory (H.S., Y.W., Y.L., G.N.), Centre for Reproductive Health, Hudson Institute of Medical Research, Clayton, Victoria 3168, Australia; 2 Monash University (H.S., Y.W., Y.L., G.N.), Clayton, Victoria 3800, Australia

    2 shared publications
  • Michael W. Parker

    Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC 3010, Australia

    1 shared publication
  • Min Zhao

    Wuxi Maternity and Children's Health Hospital (M.Z., Q.C.), Nanjing Medical University, Jiangsu 214002, China

    1 shared publication
  • Qi Chen

    Wuxi Maternity and Children's Health Hospital (M.Z., Q.C.), Nanjing Medical University, Jiangsu 214002, China; 4 Department of Obstetrics and Gynaecology (Q.C.), University of Auckland, 1142 Auckland, New Zealand

    1 shared publication
  • Stephen Tong

    Perinatal Epidemiology Group, Department of Obstetrics, Gynaecology, and Newborn Health The University of Melbourne Melbourne Victoria Australia

    1 shared publication

Latest Publications

  • Open Access

    Human HtrA4 Expression Is Restricted to the Placenta, Is Significantly Up-Regulated in Early-Onset Preeclampsia, and High Levels of HtrA4 Cause Endothelial Dysfunction

    by Harmeet Singh, Min Zhao, Qi Chen, Yao Wang, Ying Li, Tu'Uhevaha J. Kaitu'U-Lino, Stephen Tong, Guiying Nie

    Context: Preeclampsia (PE), a pregnancy-specific disorder closely associated with endothelial dysfunction and capillary leakage, is responsible for substantial maternal/fetal morbidity and mortality. PE can be classified as early-onset (34 wk); the two subsets differ in presentation and pathogenesis. Objectives: The objectives of the study were to examine serine protease high-temperature requirement factor A4 (HtrA4) expression in the placenta and other human tissues and in early-onset vs late-onset PE, to determine serum HtrA4 levels in normal pregnancy and in PE subtypes, and to investigate the effect of high levels of HtrA4 on endothelial integrity and function. Methods: Microarray data analysis and RT-PCR determined HtrA4 expression in the human placenta, various tissues, and cell lines. The serum HtrA4 protein levels were analyzed by an ELISA. The potential impact of excessive circulating HtrA4 on the maternal vasculature was determined by in vitro endothelial tube and permeability assays. Results: Human HtrA4 expression was restricted to the placenta and significantly up-regulated in early-onset but not late-onset PE. The serum HtrA4 levels in normal pregnancy increased significantly between the first and second trimesters and then remained constant. Women with early-onset but not late-onset PE showed significantly higher HtrA4 levels in serum compared with gestational age-matched controls. In cell models, high levels of HtrA4 disturbed endothelial cell tube formation and permeability in a dose-dependent manner, and this was linked to alterations in junctional proteins and microtubule organization. Conclusions: HtrA4 represents a novel placenta-specific serine protease that is altered specifically in early-onset PE with potential causal roles in endothelial dysfunction and disease development.


  • Open Access

    Activity-Modulating Monoclonal Antibodies to the Human Serine Protease HtrA3 Provide Novel Insights into Regulating HtrA Proteolytic Activities

    by Harmeet Singh, Tracy L. Nero, Yao Wang, Michael W. Parker, Guiying Nie

    Mammalian HtrA (high temperature requirement factor A) proteases, comprising 4 multi-domain members HtrA1-4, play important roles in a number of normal cellular processes as well as pathological conditions such as cancer, arthritis, neurodegenerative diseases and pregnancy disorders. However, how HtrA activities are regulated is not well understood, and to date no inhibitors specific to individual HtrA proteins have been identified. Here we investigated five HtrA3 monoclonal antibodies (mAbs) that we have previously produced, and demonstrated that two of them regulated HtrA3 activity in an opposing fashion: one inhibited while the other stimulated. The inhibitory mAb also blocked HtrA3 activity in trophoblast cells and enhanced migration and invasion, confirming its potential in vivo utility. To understand how the binding of these mAbs modulated HtrA3 protease activity, their epitopes were visualized in relation to a 3-dimensional HtrA3 homology model. This model suggests that the inhibitory HtrA3 mAb blocks substrate access to the protease catalytic site, whereas the stimulatory mAb may bind to the PDZ domain alone or in combination with the N-terminal and protease domains. Since HtrA1, HtrA3 and HtrA4 share identical domain organization, our results establish important foundations for developing potential therapeutics to target these HtrA proteins specifically for the treatment of a number of diseases, including cancer and pregnancy disorders.